CareCloud heads into today's Q1 print with options positioning at its most defensive reading of the past year.
The standout signal is the put/call ratio. It jumped to 2.31 on Wednesday — more than four standard deviations above its 20-day mean of 1.63, and the highest level recorded over the past 52 weeks. That is a sharp move even by the standards of a stock that has consistently run a relatively elevated PCR. As recently as late March, the ratio was below 1.0. It has climbed steadily since, with the single-day spike into the print suggesting traders are aggressively loading downside protection ahead of the release. The prior two earnings events are worth noting for context: the March 2026 print produced an 18% one-day gain and a 34% five-day move, while an earlier event produced a flat open before a 15% five-day rally. Those are wide-ranging outcomes, and the options market appears to be pricing in continued uncertainty rather than directional conviction.
Short interest, by contrast, is not amplifying the defensive tone. SI runs at just 1.5% of the free float — a level that does not in itself signal meaningful bearish pressure. The month-on-month change of roughly 107% sounds dramatic but reflects a base effect from a very low starting point in early April, when short positions nearly halved in a matter of days. Borrow conditions are similarly relaxed: cost to borrow is under 0.6% annualised, and the lending pool is wide open with availability near its loosest levels of the year. Nothing in the short-selling market suggests a concentrated bet against the stock.
The fundamental backdrop offers its own mixed read. The EV/EBITDA multiple of roughly 3.9x and a PE near 7.5x are undemanding for a health care technology name, and EPS momentum scores rank in the 85th percentile over 30 days — pointing to a run of upward estimate revisions heading into the print. The most recent analyst data is dated, with the freshest actionable note from Roth MKM in March 2025 lowering its target to $1.50 on a Neutral rating — well below the current $2.99 price — while Benchmark has maintained a Buy with a $4.50 target since mid-2024. The disconnect between those two stances frames the debate neatly: bulls see a cheap, estimate-beating business recovering momentum; the Neutral camp questioned whether the recovery was durable. Vanguard added nearly 486,000 shares in the most recent quarter, and American Century built a new position of over 339,000 shares, suggesting at least some institutional money is moving constructively.
Today's print will test whether the EPS momentum of recent weeks reflects genuine operational improvement — or whether the March earnings pop has left the stock facing a higher bar that the options market is now hedging against.
See the live data behind this article on ORTEX.
Open CCLD on ORTEX →ORTEX Market Intelligence content is generated by AI from a snapshot of ORTEX's proprietary data. Content is informational only and does not constitute investment advice.
